The US Food and Drug Administration (FDA) has granted orphan drug designation to Stoke Therapeutics’ antisense oligonucleotide, STK-001, a new therapy for severe and progressive genetic epilepsy Dravet syndrome.
Date:2019-08-09 Views:526
The US Food and Drug Administration (FDA) has granted orphan drug designation to Stoke Therapeutics’ antisense oligonucleotide, STK-001, a new therapy for severe and progressive genetic epilepsy Dravet syndrome.
